Table 2.

Results of the multivariate Cox-Regression analysis in the TCGA-dataset for endpoint overall survival (OS) and post accession survival (PAS) and in the Cirenajwis-dataset for endpoint OS.

Dataset	Endpoint	Covariates	Variables	HR (95%-CI)	Wald-test p-value
TCGAa	OS	Subclass	Immune	1.00	3.00 x 10−06
			Oxidative phosphorylation	2.01 (1.37–2.96)
			Cell cycle	1.51 (1.02–2.56)
			Oestrogen response/p53-pathway	1.44 (0.52–4.05)
		Gender	Female	1.00
			Male	1.02 (0.73–1.42)
		Age	Continuous	1.02 (1.01–1.03)
		Tumour stage	Stage 0 (Melanoma in situ)	1.00
			Stage I/II	0.75 (0.30–1.87)
			Stage III	1.22 (0.48–3.09)
			Stage IV	1.98 (0.64–6.19)
			Unknown	0.57 (0.20–1.62)
TCGAa	PAS	Subclass	Immune	1.00	0.008
			Oxidative phosphorylation	1.68 (1.15–2.47)
			Cell cycle	1.69 (1.14–2.51)
			Oestrogen response/p53-pathway	0.62 (0.22–1.73)
		Gender	Female	1.00
			Male	1.11 (0.80–1.55)
		Age	Continuous	1.01 (1.00–1.02)
		Tumour stage	Stage 0 (Melanoma in situ)	1.00
			Stage I/II	0.31 (0.12–0.76)
			Stage III	0.32 (0.13–0.80)
			Stage IV	0.46 (0.15–1.40)
			Unknown	0.46 (0.17–1.26)
Cirenajwisb	OS	Subclass	Immune	1.00	3,00 x 10−05
			Oxidative phosphorylation	2.55 (1.54–4.21)
			Cell cycle	2.19 (1.22–3.92)
			Oestrogen response/p53-pathway	3.16 (1.14–8.79)
		Gender	Female	1.00
			Male	1.39 (0.92–2.12)
		Age	Continuous	1.00 (0.99–1.02)
		Tumour stage	General (metastasized)	1.00
			In-transit	0.43 (0.18–1.00)
			Local	0.19 (0.06–0.63)
			Primary	0.03 (0.00–0.23)
			Regional	0.29 (0.17–0.52)

^a Number of patients in the TCGA-dataset available for survival analysis (both OS and PAS): 455. Number of events in the TCGA-dataset: 162.

^b Number of samples in the Cirenajwis-dataset available for survival analysis: 203. Number of events in the Cirenajwis-dataset: 99. Abbreviations: 95%-CI: 95%-confidence interval, HR: Hazard-ratio, OS: Overall survival, PAS: Post accession survival.